Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1997; 78(01): 075-078DOI: 10.1055/s-0038-1657504 Antiphospholipid antibodies Schattauer GmbH Stuttgart Antiphospholipid Antibodies: Predictive Value of Laboratory Tests Monica Galli Division of Haematology, Ospedali Riuniti, Bergamo, ltaly , Guido Finazzi Division of Haematology, Ospedali Riuniti, Bergamo, ltaly , Tiziano Barbui Division of Haematology, Ospedali Riuniti, Bergamo, ltaly › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (803 kb) References References 1 Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica 1993; 78: 313-318 2 Bowie EJ, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 162: 417-430 3 Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, Fernandez L, Ponce de Leon S. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a review of 500 consecutive cases. Medicine 1989; 68: 353-365 4 Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482-488 5 Koike T, Matsuura E. Anti-ß2-glycoprotein I antibody: specificity and clinical significance. Lupus 1996; 5: 378-380 6 Kandiah DA, Sheng YH, Krilis SA. ß2-glycoprotein I: target antigen for autoantibodies in the ‘antiphospholipid syndrome’. Lupus 1996; 5: 381-385 7 Galli M. Non ß2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996; 5: 388-392 8 Triplett DA. Lupus anticoagulants/antiphospholipid-protein antibodies: the great imposters. Lupus 1996; 5: 431-435 9 Barbui T, Finazzi G. Clinical trials on Antiphospholipid Syndrome: what is done and what is needed?. Lupus 1994; 3: 303-308 10 Horbach DA, v.Oort E, Donders RCJM, Derksen RHWM, de GrootPG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb Haemostas 1996; 76: 916-924 11 Long AA, Ginsberg JS, Brill-Edwards P, Jonhston M, Turner C, Denburg JA, Bensen WG, Cividino A, Andrew M, Hirsh J. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemostas 1991; 66: 520-525 12 Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691 13 Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S, Scarano L, Girolami B, Benedetti L, Girolami A. Deep venous thrombosis and lupus anticoagulant. A case-con-trol study. Thromb Haemostas 1996; 76: 187-189 14 Bongard O, Reber G, Bounameaux H, deMoerloose P. Anticardiolipin in acute venous thromboembolism. Thromb Haemostas 1992; 67: 724 15 The Antiphospholipid Antibodies in Stroke Study Group (APASS). Clinical, radiological and pathological aspects of cerebrevascular disease associated with antiphospholipid antibodies. Stroke 1993; 24 I I-120-I-123 16 Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 0997-1002 17 Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palouso T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-27 18 Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palouso T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609 19 Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemostas 1996; 75: 456-459 20 Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D’Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536 21 Vianna JL, Khamashta MA, Ordi-Ros FontJ, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M, Vilardell M, Hughes GRV. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3-9 22 Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99: 624-628 23 Levine SR, Brey RL, Joseph CML. Havstad S on behalf of the APASS. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 1992; 23 (suppl 01) 01 29-32 24 Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticadiolipin antibodies in young adults with cerebral ischemia. Stroke 1992; 23: 189-193 25 Hamsten A, Bjorkholm M, Norberg R, deFaire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular event. Lancet 1986; i 113-116 26 Sletness KE, Smith P, Abedlnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies and myocardial infarction and their relation to mortality, reinfarction and non-haemorrhagic stroke. Lancet 1992; 339: 451-453 27 Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism and intensity of warfarin anticoagulation. Thromb Haemostas 1996; 75: 859-868 28 Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and ß2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-623
